These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32226580)

  • 41. A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events.
    Kashiwabara K; Matsuyama Y; Ohashi Y
    Ther Innov Regul Sci; 2014 Jul; 48(4):444-452. PubMed ID: 30235573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs.
    Schmidt AF; Klugkist I; Klungel OH; Nielen M; de Boer A; Hoes AW; Groenwold RH
    J Clin Epidemiol; 2015 Apr; 68(4):387-96. PubMed ID: 25554520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.
    Jiang W; Wick JA; He J; Mahnken JD; Mayo MS
    J Biopharm Stat; 2018; 28(5):824-839. PubMed ID: 29172970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Online control of the False Discovery Rate in group-sequential platform trials.
    Zehetmayer S; Posch M; Koenig F
    Stat Methods Med Res; 2022 Dec; 31(12):2470-2485. PubMed ID: 36189481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous event monitoring via a Bayesian predictive approach.
    Di J; Wang D; Brashear HR; Dragalin V; Krams M
    Pharm Stat; 2016; 15(2):109-22. PubMed ID: 26643012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case for Bayesianism in clinical trials.
    Berry DA
    Stat Med; 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PubMed ID: 8248653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint.
    Liu GF
    Pharm Stat; 2018 Feb; 17(1):61-73. PubMed ID: 29125220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The power prior: theory and applications.
    Ibrahim JG; Chen MH; Gwon Y; Chen F
    Stat Med; 2015 Dec; 34(28):3724-49. PubMed ID: 26346180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bayesian versus frequentist hypotheses testing in clinical trials with dichotomous and countable outcomes.
    Zaslavsky BG
    J Biopharm Stat; 2010 Sep; 20(5):985-97. PubMed ID: 20721786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Group sequential control of overall toxicity incidents in clinical trials - non-Bayesian and Bayesian approaches.
    Yu J; Hutson AD; Siddiqui AH; Kedron MA
    Stat Methods Med Res; 2016 Feb; 25(1):64-80. PubMed ID: 22407172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
    Sambucini V
    Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics.
    Morita S; Thall PF; Müller P
    Stat Biosci; 2010 Jul; 2(1):1-17. PubMed ID: 20668651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Computations for group sequential boundaries using the Lan-DeMets spending function method.
    Reboussin DM; DeMets DL; Kim KM; Lan KK
    Control Clin Trials; 2000 Jun; 21(3):190-207. PubMed ID: 10822118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction models for clustered data with informative priors for the random effects: a simulation study.
    Ni H; Groenwold RHH; Nielen M; Klugkist I
    BMC Med Res Methodol; 2018 Aug; 18(1):83. PubMed ID: 30081875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficiency in sequential testing: Comparing the sequential probability ratio test and the sequential Bayes factor test.
    Stefan AM; Schönbrodt FD; Evans NJ; Wagenmakers EJ
    Behav Res Methods; 2022 Dec; 54(6):3100-3117. PubMed ID: 35233752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bayesian adaptive design for device surveillance.
    Murray TA; Carlin BP; Lystig TC
    Clin Trials; 2013 Feb; 10(1):5-18. PubMed ID: 23188891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.